Viva Biotech Holdings VBIZF Stock
Viva Biotech Holdings Price Chart
Viva Biotech Holdings VBIZF Financial and Trading Overview
| Viva Biotech Holdings stock price | 0.2 USD |
| Previous Close | 0.2 USD |
| Open | 0.3 USD |
| Bid | 0.15 USD x 1000000 |
| Ask | 0.2 USD x 250000 |
| Day's Range | 0.3 - 0.3 USD |
| 52 Week Range | 0.19 - 0.43 USD |
| Volume | 100 USD |
| Avg. Volume | 95 USD |
| Market Cap | 618.28M USD |
| Beta (5Y Monthly) | 1.516 |
| PE Ratio (TTM) | 29.5 |
| EPS (TTM) | 0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | June 16, 2021 |
| 1y Target Est | N/A |
VBIZF Valuation Measures
| Enterprise Value | 668.08M USD |
| Trailing P/E | 29.5 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.3575044 |
| Price/Book (mrq) | 1.1623371 |
| Enterprise Value/Revenue | 0.386 |
| Enterprise Value/EBITDA | 1.734 |
Trading Information
Viva Biotech Holdings Stock Price History
| Beta (5Y Monthly) | 1.516 |
| 52-Week Change | -18.47% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 0.43 USD |
| 52 Week Low | 0.19 USD |
| 50-Day Moving Average | 0.3 USD |
| 200-Day Moving Average | 0.29 USD |
VBIZF Share Statistics
| Avg. Volume (3 month) | 95 USD |
| Avg. Daily Volume (10-Days) | 100 USD |
| Shares Outstanding | 2.1B |
| Float | 1.02B |
| Short Ratio | N/A |
| % Held by Insiders | 43.26% |
| % Held by Institutions | 8.79% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 12.70% |
| Operating Margin (ttm) | 8.62% |
| Gross Margin | 37.90% |
| EBITDA Margin | 22.28% |
Management Effectiveness
| Return on Assets (ttm) | 1.69% |
| Return on Equity (ttm) | 6.88% |
Income Statement
| Revenue (ttm) | 1.73B USD |
| Revenue Per Share (ttm) | 0.82 USD |
| Quarterly Revenue Growth (yoy) | -10.69% |
| Gross Profit (ttm) | 655.56M USD |
| EBITDA | 385.38M USD |
| Net Income Avi to Common (ttm) | 219.76M USD |
| Diluted EPS (ttm) | 0.01 |
| Quarterly Earnings Growth (yoy) | 94.00% |
Balance Sheet
| Total Cash (mrq) | 1.09B USD |
| Total Cash Per Share (mrq) | 0.52 USD |
| Total Debt (mrq) | 1.33B USD |
| Total Debt/Equity (mrq) | 33.21 USD |
| Current Ratio (mrq) | 1.508 |
| Book Value Per Share (mrq) | 0.253799 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 232.22M USD |
| Levered Free Cash Flow (ttm) | -175200880 USD |
Profile of Viva Biotech Holdings
| Country | United States |
| State | N/A |
| City | Shanghai |
| Address | No.735, Ziping Road |
| ZIP | 201318 |
| Phone | 86 21 6089 3288 |
| Website | https://www.vivabiotech.com.cn |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2169 |
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and complex structure determination, ADME & PK/PD studies of PROTAC molecules, and XDC platforms, such as XDC conjugation and quality study, and XDC chemistry research and development. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides research services. The company was incorporated in 2008 and is headquartered in Shanghai, China.
Q&A For Viva Biotech Holdings Stock
What is a current VBIZF stock price?
Viva Biotech Holdings VBIZF stock price today per share is 0.2 USD.
How to purchase Viva Biotech Holdings stock?
You can buy VBIZF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Viva Biotech Holdings?
The stock symbol or ticker of Viva Biotech Holdings is VBIZF.
Which industry does the Viva Biotech Holdings company belong to?
The Viva Biotech Holdings industry is Biotechnology.
How many shares does Viva Biotech Holdings have in circulation?
The max supply of Viva Biotech Holdings shares is 2.09B.
What is Viva Biotech Holdings Price to Earnings Ratio (PE Ratio)?
Viva Biotech Holdings PE Ratio is 19.72800000 now.
What was Viva Biotech Holdings earnings per share over the trailing 12 months (TTM)?
Viva Biotech Holdings EPS is 0.01 USD over the trailing 12 months.
Which sector does the Viva Biotech Holdings company belong to?
The Viva Biotech Holdings sector is Healthcare.


